

## PB2135 TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS

**Topic:** 14. Myeloma and other monoclonal gammopathies - Clinical

Anita D'souza<sup>\*1</sup>, Tiffany Quock<sup>2</sup>, Ansgar Conrad<sup>2</sup>, Michael S. Broder<sup>3</sup>, Ashis K. Das<sup>3</sup>, Eunice Chang<sup>3</sup>, Marian H. Tarbox<sup>3</sup>

<sup>1</sup>Medical College Of Wisconsin, Milwaukee, United States; <sup>2</sup>Prothena Biosciences Inc., South San Francisco, United States; <sup>3</sup>Phar (Partnership For Health Analytic Research), Beverly Hills, United States

### Background:

Treatment options for AL amyloidosis remain limited.

### Aims:

To describe current patterns of medication use in patients with newly diagnosed AL amyloidosis.

### Methods:

This retrospective analysis used 2017-2020 data from the Merative<sup>®</sup> MarketScan<sup>®</sup> Commercial and Medicare Supplemental and the IQVIA Pharmetrics Plus<sup>®</sup> databases to identify adult patients (newly diagnosed) with  $\geq 1$  inpatient or  $\geq 2$  outpatient claims for AL amyloidosis (ICD-10-CM code E85.81) in any diagnosis field during the identification period (1/1/2018-12/31/2020). The first observed AL amyloidosis diagnosis date was the index date. Continuous enrollment in a health plan during the 1 year before (baseline) and  $\geq 3$  months after (follow-up) index was required. Patients with an AL amyloidosis diagnosis during the baseline period or who received no treatment were excluded. Study outcomes included demographic/clinical characteristics and treatment patterns. We reported on lines of treatment, duration (defined as continuous use from first line to end of days' supply without a gap of  $\geq 120$  days), and adherence (proportion of days covered, PDC,  $\geq 80\%$  while persistent) to first-line therapy.

### Results:

The final sample consisted of 338 patients with newly diagnosed AL amyloidosis. Mean (SD) age at diagnosis was 61.2 (9.1) years and 42.3% of patients were female. As the first-line therapy, 72.5% patients received bortezomib-containing regimens, whereas only 13.9% received daratumumab-containing regimens. The most common first-line treatment was bortezomib-cyclophosphamide-dexamethasone (34.0%), with mean (SD) duration of 138.7 (100.9) days and mean (SD) PDC of 98.4% (5.8%). Overall, for patients with first-line treatment (except for hematopoietic stem cell transplant [HSCT]), the mean (SD) duration was 143.2 (136.7) days, mean (SD) PDC was 0.978 (0.064), and 97.2% were adherent (PDC  $\geq 80\%$ ). For patients with second-line treatment, the most common was HSCT (23.4%), followed by bortezomib-daratumumab-dexamethasone and daratumumab alone (both 11.1%).

**Summary/Conclusion:** Bortezomib-containing regimens were the most common first-line therapy and HSCT was the most common second-line therapy. Even though treatment availability is limited for AL amyloidosis, newly diagnosed patients in this study were highly adherent to their first-line therapy. Additional therapies for AL amyloidosis are currently under development.

**Copyright Information:** (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

**Abstract Book Citations:** Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

**Disclaimer:** Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.